Albert Bourla - 13 Feb 2025 Form 4 Insider Report for PFIZER INC (PFE)

Reporting relationship: Chairman & CEO, Director
Issuer ticker: PFE
Reported as of: 13 Feb 2025
Net transaction value: +$16,025
SEC form: 4
Accepted by SEC: 18 Feb 2025, 11:23:37 UTC
Prior SEC filing: 15 Jan 2025
Next SEC filing: 25 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Shanice A. Reid, by power of atty., for Albert Bourla

Key filing fact

Albert Bourla filed Form 4 for PFIZER INC (PFE) on 18 Feb 2025.

Key facts

This page summarizes Albert Bourla's Form 4 filing for PFIZER INC (PFE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Feb 2025, 11:23.

Change

Previous filing in this sequence was filed on 15 Jan 2025.
Current net transaction value: +$16,025.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PFE transaction Derivative

Phantom Stock Units SSP

Award

Transaction value: $16,025
Shares: +625
Change %: +0.09%
Price: $25.64
Shares after: 702,791
Date: 13 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 625
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each unit represents one phantom share of common stock.

Footnote F2

These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.